LENZ Therapeutics Inc（LENZ）财务数据LENZLENZ Therapeutics Inc

Evaluating the bottom line, LENZ Therapeutics, Inc. maintains a gross margin of 94.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -622.89%, while the net margin is -581.81%. These profitability ratios, combined with a Return on Equity (ROE) of -59.21%, provide a clear picture of how effectively LENZ converts its operational activities into shareholder value.

In the context of the broader market, LENZ competes directly with industry leaders such as MDWD and OTLK. With a market capitalization of $160.56M, it holds a significant position in the sector. When comparing efficiency, LENZ's gross margin of 94.90% stands against MDWD's 10.90% and OTLK's -95.00%. Such benchmarking helps identify whether LENZ Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

LENZ has shown inconsistent revenue growth, with total revenue of $5 million in Q2 2025 and $12.5 million in Q3 2025, but net income remains negative, with a net loss of $41.49 million reported in Q1 2026. The gross margin has fluctuated, showing a high of 100% in Q2 and Q3 of 2025, but dropping to 43.4% in Q1 2026.